Xenon Reports Q3 2024 Financial Results and Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/14/2026
- Nasdaq ends down as chipmakers fall and bank earnings roll in
- Oil prices settle mixed, focus on US-Russia diesel deal, Saudi Yemen attacks
- JPMorgan shares edge lower after third-quarter FICC revenue miss
- Fed’s Waller says US bond yield rise driven by growth, not inflation
- Wells Fargo beats profit estimates despite revenue miss
Xenon Pharmaceuticals (XENE) PT Raised to $56 at RBC Capital
November 13, 2024 6:48 AM ESTRBC Capital analyst Brian Abrahams raised the price target on Xenon Pharmaceuticals (NASDAQ: XENE) to $56.00 (from $55.00) while maintaining a Outperform rating.
The analyst comments "All remains on track, heading towards a big 2025 for data, with investigator MDD data 1H25 - which we believe... More



